ABIVAX Société Anonyme (NASDAQ:ABVX) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a report issued on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

Separately, Morgan Stanley upped their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an equal weight rating in a report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $32.00.

ABIVAX Société Anonyme Price Performance

Shares of ABIVAX Société Anonyme stock opened at $15.52 on Monday. The stock has a 50-day moving average price of $14.51. ABIVAX Société Anonyme has a fifty-two week low of $7.99 and a fifty-two week high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several large investors have recently bought and sold shares of ABVX. Capstone Investment Advisors LLC acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth about $618,000. Ghisallo Capital Management LLC purchased a new position in ABIVAX Société Anonyme in the 4th quarter worth approximately $642,000. Rosalind Advisors Inc. acquired a new position in shares of ABIVAX Société Anonyme during the 1st quarter worth approximately $5,411,000. Franklin Resources Inc. purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $13,630,000. Finally, Great Point Partners LLC acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $16,585,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.